The aim of this study was to investigate means of increasing the efficiency with which cancer cell death following local radiation therapy (RT) is translated into the generation of tumor immunity since, if this were to be achieved, it would be expected to enhance the rates of disease-free recurrence and survival. Our investigations centered around the use of interleukin-3 (IL-3), expressed intratumorally using an inducible adenoviral vector, to alter the immunogenicity of established murine TRAMP-C1 prostate cancer receiving a course of fractionated local RT (7 Gy per fraction per day for 5 days). Because high systemic levels of IL-3 can be associated with toxicity, a tetracycline-regulated gene delivery system was employed. The results show that while intratumoral IL-3 expression or RT alone caused a modest delay in TRAMP-C1 tumor growth, the combination was synergistic with 50% of mice being cured and developing a long-term, tumor-specific state of immunity. Immunological analyses performed on splenic lymphocytes demonstrated that, compared to RT or IL-3 alone, combined treatment significantly increased the number of tumorspecific IFN-g-secreting and cytotoxic T cells. The study demonstrates that tetracycline-regulated IL-3 gene expression within tumors can enhance the immune response to prostate cancer and this can augment the efficacy of a course of RT without additional side effects.
Introduction
Radiation therapy (RT) is a front line treatment for human prostate cancer. While it is very effective in early stage disease, it is less able to deal with higher tumor burden and local RT does not impact on micometastatic disease that has spread beyond the capsule. One current experimental approach to increasing local control is to increase the dose of radiation to the tumor using delivery techniques that better confirm the field to fit the tumor site; however, this increases the risk of missing local microscopic extensions of disease and perhaps of longterm complications as a consequence of injury to adjacent normal tissues, normally rectum and bladder. Supplementing RT with a different adjunctive therapy such as immunotherapy (IT) that would increase the probability of achieving local control while at the same time generating systemic antitumor immunity that might help eradicate minimal residual and micrometastatic disease is therefore an attractive option. The combination of RT with IT has been shown to be effective in preclinical models of renal adenocarcinoma, 1 prostate carcinoma, 2 and other tumors. 3 The attraction of RT combined with IT is increased by findings that irradiation can modulate expression of several classes of genes in both murine and human cancers, 4 such as Fas, MHC-1, ICAM-1, and MUC-1, that might enhance their ability to serve as immune targets. 2, [5] [6] [7] On the other hand, while there is evidence that RT generates 'danger' signals that might mature dendritic cells (DCs) to present tumor antigen 8, 9 there is no good evidence that this occurs in the clinic and such signals may be too weak to be effective. In a recent randomized phase II clinical trial study, 10 addition of recombinant vaccine administration to standard RT in patients with clinically localized prostate cancer showed that vaccination was safe and the generation of a PSAspecific cellular immune response was enhanced following RT. We have shown in previous studies that expression of interleukin-3 (IL-3) gene within tumors can enhance the immunogenicity of even classically nonimmunogenic tumors, 11 without altering their intrinsic radiosensitivity, and this enhances the effects of radiation therapy (RT), allowing a long-term state of immunity to develop after the primary tumor regresses. At least two mechanisms of IL-3 action were proposed by us and others. [11] [12] [13] [14] [15] One was by altering the phenotypic expression of cell adhesion molecules and of MHC class I by tumor cells. Another was by improving presentation of putative tumor antigens through maturation of DCs.
Recently, we demonstrated in a very preliminary study that adenoviral IL-3 gene delivery (Adeno-IL3) into murine prostate cancers (TRAMP-C2) 16 could enhance the efficacy of RT. This study extends these findings mechanistically in a TRAMP-C1 model. Further, since long-term expression of IL-3 is associated with some hematological side effects, manifested in the mouse as splenomegaly, we have refined the adenoviral delivery system by employing a tetracycline-regulated vector.
Materials and methods
Mice, tumors, and tumor irradiation C57BL/6J mice were purchased from the National Laboratory Animal Center, Taiwan. Male mice, 7-to 8-week old, were used for experiments. TRAMP-C1 tumors that developed in TRAMP transgenic mice 17 and that are syngeneic to C57BL/6J mice were kindly provided by Dr NM Greenberg. Tumors were generated by inoculating 5 Â 10 5 viable TRAMP-C1 cells into the right thighs of mice. After 10 days, when the tumors had reached 4-6 mm in diameter they were irradiated with 7 Gy per day for 5 consecutive days for a total dose of 35 Gy delivered to the tumor site using 6 MV X-rays from a linear accelerator with a dose rate of 2.3 Gy/min and a 1.5 cm bolus on the surface, with the rest of body shielded. Tumor diameters were measured in three mutually orthogonal dimensions at 2-3 day intervals with a vernier caliper and the mean values calculated to assess tumor growth until 12 mm was reached, when the mice were euthanized. The recommendations of the approved guide for the care and use of laboratory animals by the Institutional Animal Care and Use Committee (IACUC) of National Tsing Hua University, Taiwan, were followed at all times.
In vitro irradiation of cells was performed using a cobalt source in the Nuclear Science and Technology Development Center, National Tsing Hua University, Taiwan, with a dose rate of 1.1 Gy/min. Clonogenic survival after irradiation was assessed by plating varying cell numbers in 100 mm diameter Petri dishes and counting colonies of greater than 50 cells on day 12 after staining by Giemsa (Sigma-Aldrich, St Louis, MO). The surviving fraction was calculated by colonies counted/ (cells seeded Â (plating efficiency of untreated control cells)).
In vitro gene transduction
The Adeno-X and Adeno-X-Tet-On expression systems (BD, Clontech, San Jose, CA; Cat. No. 631513 and 631508, respectively) were used as described by the manufacturer to introduce and express full-length IL-3 cDNA in cultured tumor cells (in vitro) and growing tumors (in vivo/in situ). The former adenovirus expression vector was used with a CMV promoter to drive constitutive expression of IL-3 or b-gal genes. The latter is a dual vector system where an Adeno-X-Tet-on virus produces rtTA (reverse tetracycline-controlled transactivator) in response to binding of tetracycline (or its analog, doxycycline (Dox)) to a Tet-responsive element (TRE), 18 which controls expression of Adeno-X-TRE-IL3 or b-gal. The adenovirus preparation was enriched using an Adeno-X virus purification kit (Clontech; Cat. No. 631518) and titer determined by endpoint dilution assay using an Adeno-X Rapid Titer Kit (BD, Clontech).
The Tet-on system was tested using b-gal expression. TRAMP-C1 cells were cultured in eight-well chamber slides (Nalgen Nunc International, Rochester, NY) at a plating density of 1 Â 10 5 cells per well. At 24 h after plating, varying concentrations of Adeno-X-Tet-on virus and Adeno-X-TRE-bgal virus were added. Immediately after infection, Dox (Sigma-Aldrich, St Louis, MO) was added in the final concentration of 1 mg/ml. After 24 h, cells were fixed with 4% paraformaldehyde (SigmaAldrich) for 15 min at room temperature and expression assessed by staining for 1 h using an X-gal staining assay kit (Gene Therapy Systems Inc., San Diego, CA). For the IL-3 adenoviral vectors, mouse IL-3 protein was measured using an enzyme-linked immunosorbant assay (ELISA) kit (Endogen, Rockford, IL; Cat. No.: ENDEM-IL3).
In vivo gene transduction and tumor irradiation Adv-X-Tet-On virus (1 Â 10 7 IFU) and Adv-X-TRE-IL3 virus (1 Â 10 7 IFU) or Adeno-X-TRE-bgal virus (1 Â 10 7 IFU) was injected intratumorally into each of four quadrants of a tumor for a total volume of 60 ml of PBS -1, 1, and 3 days following the first dose of a fractionated RT protocol (7 Gy/fraction for 5 days to a total dose of 35 Gy). Dox, or control PBS, was delivered by Alzet osmotic pumps (DURECT Corporation; Cat. No: 2002, Cupertino, CA) implanted subcutaneous (s.c.) under the skin of mice slightly posterior to the scapulae 1 h before the first injection of virus. The pumps contained 200 ml of Dox at 1 mg/ml for secretion at a rate of 1 ml per hour for 7 days. Pumps were not replaced after this time.
Immune response assays ELISPOT was used to assess tumor-specific splenic lymphocyte responses. Spleens were taken 14 days after the last virus injection, or when the tumor reached 1 cm diameter, whichever was the sooner. Spleen cell preparations were depleted of red cells by osmotic lysis and lymphocytes restimulated by adding irradiated (35 Gy) TRAMP-C1 or B16 melanoma cells (ATCC number: CRL-6745) at 25:1 responder-to-stimulator ratios for 48 h in the presence of 10 U/ml hIL-2 (BioSource International, Camarillo, CA). ELISPOT assays were performed in MultiScreen-HA96 plates (Millipore, Bedford, MA) coated with anti-IFN-g or anti-IL-4 antibodies (BD Pharmingen, San Jose, CA). After washing and blocking with 10% fetal bovine serum/phosphate-buffered saline (FBS/PBS), restimulated splenocytes were added and incubated for 24 h. Plates were washed and incubated at 41C with biotinylated anti-IFN-g or anti-IL-4 Ab (BD Pharmingen). HRP-avidin D (Vector Laboratories, Burlingame, CA) diluted 1/2000 in blocking buffer (10% FBS/PBS) was added and the plates incubated at room temperature for 45 min. Spots were developed by adding 150 ml/well substrate buffer containing 0.4 mg/ml 3-amino-9-ethyl-carbazole (AEC tablets; Sigma-Aldrich) in 0.05 M sodium acetate buffer (pH 5.0) and 0.012% hydrogen peroxide. The plate was kept in the dark for 20 min and spots were counted under a dissecting microscope.
Tumor-specific cytotoxic CD8 T lymphocytes were assessed in splenocyte preparations depleted of non-CD8 T cells using a cocktail of monoclonal antibodies (Cat. # 130-090-859, Miltenyi Biotech, Auburn, CA) bound to magnetic beads and passing them through a magnetic field of a MACS separator (Miltenyi Biotech). Cytotoxic function was analyzed using a CyToxiLux kit (OncoImmunin Inc., Gaithersburg, MD). Briefly, target (TRAMP-C1) or nontarget (B16 melanoma) tumor cells were fluorescently labeled with red dye and co-incubated with CD8 T cells. After 1 h, cells were resuspended in the presence of a fluorogenic caspase substrate. Following incubation and washing, samples were analyzed by flow cytometry (CyFlow, Partec, GmbH) for the increased green fluorescence in dying cells. The percentage of double positive cells was used as the index of cytotoxicity. 
RT-PCR analysis
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA). Of total RNA, 2 mg, was first reverse transcribed to cDNA by Omniscript reverse transcriptase (Quiagen, Valencia, CA). The primer pairs for ICAM-1 were (5 0 primer: 5 0 -AAGGGCTGGCAT TGTTCTCTAA-3 0 and 3 0 primer: 5 0 -AGCGCAGCGG CAGGGTTCT-3 0 ) and for b-actin were (5 0 primer: 5 0 -GGTGACGAGGCCCAGAGCAA-3 0 and 3 0 primer:
Characterization of tumor-infiltrating host cells and tumor cell surface markers Tumors were disaggregated into single cell preparations using dispase, 11 and host cell populations identified by flow cytometry using CyFlow (Partec, GmbH). Lymphocytes were identified by gating using splenocytes to define the appropriate FSC vs SSC region. of variance (ANOVA) test or Student's t-test using a twotailed distribution. The P-values were calculated using the GraphPad Prism software version 3.03 package (GraphPad Software Inc., San Diego, CA).
Results
Characterization of the tetracycline-induced adenovirus expression system in vitro ELISA of supernatants from TRAMP C-1 cells infected in vitro was used to characterize some of the variables involved in production of IL-3 by the Adv-X-TRE-IL-3/ Adv-X-Tet-On gene transfer system (Figure 1) . Addition of Dox from 0.01 up to 1 mg/ml to cells infected at an multiplicity of infection (MOI) of 10:1 led to IL-3 production that increased with time (Figure 1a, b) and there was no evidence of viral toxicity up to an MOI of 20:1 (Figure 1c) . Regulation of gene expression by Dox was confirmed using the Adv-X-TRE-bgal virus (Figure 1d ).
Influence of in vivo IL-3 expression on the growth of TRAMP-C1 tumor The Tet-On gene transfer system was tested in vivo by injecting 10
7 Adv-X-Tet-On particles along with an equal number of Adv-X-TRE-IL3 or Adv-X-TRE-b-gal viruses into each of four quadrants of 4-6 mm diameter TRAMP-C1 tumors in 15 ml volumes per site. This was repeated three times every other day. Osmotic pumps that were designed to deliver Dox at a rate of 1 mg/ml per hour for 7 days were implanted s.c. in the mice one day before the first virus injection. This protocol was sufficient to produce measurable levels of IL-3 in serum (Figure 2a ) and within tumors 3 and 7 days (Figure 2b ) after the last injection of viruses, indicating that expression lasted for at least a week.
As can be seen in Figure 2c , switch-on of IL-3, but not b-gal, by Dox significantly delayed TRAMP-C1 growth compared with PBS-injected controls. Dox administration alone did not affect the rate of tumor growth (data not shown). Although elevated levels of IL-3 were found in the tumor up to 1 week, mice did not develop the splenomegaly (Figure 2d ) that is generally found in mice bearing tumors constitutively expressing IL-3 either by adenovirus or retrovirus. 19 The influence of IL-3 gene transfer on the tumor response to RT The above experimental design was used to test the effect of IL-3 gene expression on the response of TRAMP-C1 tumors to RT in vivo. Adv-X-Tet-On/Adv-X-TRE-IL3 viruses were injected into 4-6 mm diameter TRAMP-C1 tumors on days À1, 1, and 3 days relative to the first dose of a fractionated RT protocol (total dose of 35 Gy delivered in 7 Gy/fraction for 5 days). The growth kinetics of the tumors in one of three repeated experiments, each of which gave similar findings, are presented in Figure 3a .
TRAMP-C1 is a fast growing tumor with a volume doubling time of 2 days. Dox-regulated IL-3 expression slowed growth, as did fractionated RT, causing 5 and 13 days of tumor growth delay, respectively. However, all tumors in these groups continued to grow progressively. In contrast, the combined treatment of RT with Figure 3 (a). The influence of intratumoral tet-on Adeno-X-TRE-IL3 gene therapy, as described in Figure 2 , on TRAMP-C1 tumor response to fractionation radiation therapy. 1 Â 10 7 PFU Adeno-XTet-on and Adeno-X-TRE-IL3 viruses in 60 ml were given -1, 1, and 3 days (arrows) relative to the first of 5 daily 7 Gy doses of RT (solid line rectangular area). Dox was administered by osmotic pump for 7 days (dotted rectangular area) starting 1 day before virus injection. Parentheses represent the number of mice with tumors/the number of mice injected in one representative of three experiments. (b) The influence of Adeno-X-IL3 gene transduction at an MOI of 100 on the in vitro response of TRAMP-C1 cells to 0, 2, and 4 Gy irradiation. Irradiation was delivered 24 h after virus infection and the surviving fraction was measured by clonogenic assay. Adeno-X-IL3 reduced the plating efficiency of TRAMP-C1 cells, but did not alter their response to irradiation. *Po0.05 by Student's t-test.
Dox-regulated IL-3 gene expression extended tumor growth delay to 21 days and four out of eight mice tumors regressed completely with the mice remaining tumor-free for more than 2 months. Three of the mice that had rejected tumor were rechallenged by s.c. inoculation of 1 Â 10 6 viable TRAMP-C1 cells and all resisted the re-challenge (data not shown), indicating that long-term immunity had developed.
We had shown previously that IL-3 gene transfection of fibrosarcoma cells did not alter their intrinsic radiosensitivity in vitro. We confirmed this in TRAMP-C1 cells using the Adeno-X-IL3 vector system with the constitutive CMV promoter. TRAMP-C1 cells at 80% confluence were transduced with Adv-X-IL3 at an MOI of 100. Medium was collected one day later and IL-3 content, as measured by ELISA, was 213782 pg/ml/ 10 6 cells. Control TRAMP-C1 cells did not produce measurable IL-3. Cells were irradiated at this time and plated for clonogenic survival. Adeno-X-IL3 slightly decreased the plating efficiency of TRAMP-C1 (Figure 3b ), but the response to 2-4 Gy was not affected. The observed in vivo radiation sensitivity of IL-3-transfected tumors in Figure 3a cannot therefore be ascribed to a change in intrinsic cellular radiosensitivity.
The immune response following combined RT and IL-3 gene therapy Several experiments were undertaken to determine if the immune system was responsible for the tumor regression following the combined RT plus Adv-X-TRE-IL-3 gene treatment. First, the change in the proportions of different cell types within TRAMP-C1 tumors was examined one day after last tumor irradiation with and without IL-3 gene therapy. RT significantly increased the intratumoral population of cells with FSC vs SSC flow cytometry profiles corresponding to lymphocytes from around 3 to 20% (data not shown). IL-3-treatment did not further increase the lymphocyte population. Macrophages, as detected by CD11b (Mac-1) staining, comprised 24.4% of the total cells in control tumor (Figure 4a ). This increased to 29.5% in RT-treated tumor (Figure 4b) . A similar increase was found for Adv-X-TRE-IL3-treated tumors (30.9%) (Figure 4c ). The combined treatment of RT and Adv-X-TRE-IL3 further enhanced the percentage of Mac-1 þ cells to 38.5% ( Figure 4d ). As Mac-1 is more highly expressed on infiltrating monocytes than mature macrophages (13), these results indicate that both RT and Adv-X-TRE-IL3 treatment results in infiltration of Mac-1 þ cells from the periphery, and this was further enhanced when the two treatments were given. The effects of short-term Dox-induced IL-3 and RT on tumor-specific T-cell responses were then assessed by ELISPOT ( Figure 5 ) and CTL assay ( Figure 6 ) using spleens taken from the mice 14 days after the last virus injection or when tumors reached 1 cm diameter, whichever was the sooner. Almost no immune response was detected by ELISPOT assay in mice bearing TRAMP-C1 tumors without treatment ( Figure 5 ). Both intratumoral injection of Adv-X-Tet-on/Adv-X-TRE-IL3 virus and RT generated modest immune responses. In contrast, the combined treatment markedly increased tumor-specific T-cell responses. Intriguingly, whereas IL3 gene expression alone resulted in a predominantly IL-4 response, RT generated more IFN-g producing cells, especially in the combined treatment group.
Cytotoxicity assays showed that CD8 þ positive T cells isolated from the same splenocytes as used in Figure 5 were more cytotoxic towards TRAMP-C1 cells in vitro if mice received the combined RT plus IL-3 treatment (Figure 6d ) than if they came from mice receiving either single treatment (Figure 6b , c) or PBS (Figure 6a ). These responses were tumor-specific because responses did not occur when syngeneic B16 melanoma cells were used as stimulators in the ELISPOT assay (data not shown) or as target cells in CTL assay (Figure 6f ).
The influence of IL-3 gene transfer and radiation on tumor phenotypes
We, 11, 12 and others, 13, 15 have previously shown that constitutive IL-3 gene expression can alter tumor phenotype, increasing MHC class I and CD44 expression. As radiation-induced changes in MHC class I, ICAM-1, and Fas expression by tumor cells irradiated in vitro also have been reported [5] [6] [7] we examined expression of these molecules on TRAMP-C1 cells with and without Doxregulated IL-3 expression 4 h following a single in vitro dose of 0 or 7 Gy. Radiation was given 24 h after Dox treatment. TRAMP-C1 cells express low levels of MHC class I, a moderate level of Fas, and no ICAM-1 (Figure 7a) . Either irradiation or IL-3 production increased MHC class I (Figure 7b ), ICAM-1 (Figure 7c) , and Fas protein (Figure 7d ) expression. The combined treatment further increased expression only for ICAM-1. The ability of irradiation to increase ICAM-1 expression was confirmed at the mRNA level by reverse transcription-polymerase chain reaction (RT-PCR) (not shown).
Discussion
This study shows that tetracycline-regulated intratumoral expression of IL-3 using an adenovirus vector potentiated the response of established murine prostate tumors (TRAMP-C1) to RT resulting in a significant number of complete regressions and the development of a state of long-term immunity. These data extend our studies using IL-3 retrovirus-transfected fibrosarcoma tumors 11 and Adv-IL3 with a constitutive promoter, 16 as well as being consistent with results of others in other tumor models. 1, 20, 21 The increased response to RT in this system was not due to IL-3-induced alteration in the intrinsic cellular radiosensitivity of the tumor cells. Rather, the evidence is overwhelming that the enhanced response was due to cooperative effects of RT with an IL-3 augmented tumorspecific immune response. Furthermore, we demonstrated that the side effects associated with production of persistent high levels of IL-3 19, 22 can be reduced by the tetracycline-regulated expression system. RT alone increased intratumoral lymphocyte representation, however tumor-specific immune responses in the spleen were only modestly increased over unirradiated controls, as assessed by ELISPOT and CTL assays. The extent to which responses are generated may depend upon the model and where responses are assessed. For example, RT alone was recently shown to be able to stimulate intratumoral lymphocytes responsive to both a foreign model Ag and an endogenous tumor Ag in an OVAexpressing B16 melanoma tumor model. 3 However, while RT seems able to generate 'danger' signals in general there is little to suggest that these are potent 9 for the development of specific adaptive immunity. Immune stimulation may be additionally required and a recent randomized phase II clinical trial study. 10 using a recombinant PSA vaccine combined with RT in patients with clinically localized prostate cancer has shown the promise of this strategy. Following RT, PSA-specific cellular immune responses to vaccination were enhanced. It would seem logical to take further steps to combine RT with tumor IT in the clinic. We, and others, have examined the potential of IL-3 to act as adjuvant IT in combination with RT. As with other cytokine-based immunotherapeutic approaches, the mechanism may be complex. 23, 24 IL-3 is known to participate in determining the development and functional behavior of macrophages. 25 It can expand a subset of macrophages 13 with increased expression of coaccessory molecules, including MHC class II molecules and IL-1. 25, 26 In cooperation with TNF-a, it stimulates growth of DCs, which are professional antigen presenting cells (APC). 27 It has been shown to enhance the presentation of OVA antigen by macrophage-like APC in the context of class I MHC to CD8 þ CTL. 15, 28 Furthermore, it has been recently shown that IL-3 and IFN-b could prime DCs from peripheral blood mononuclear cells (PMBC) to induce antigen-specific CD8 þ T cells in melanoma patients. 29, 30 In this study, we found that even short-term intratumoral IL-3 production, switched on by Dox, could delay tumor growth, even though it could not cure mice of established tumors. Splenocytes isolated from these mice produced more IL-4 in response to in vitro stimulation with irradiated TRAMP-C1 cells than controls, which is in consistent with knowledge of the function of IL-3 in enhancing IL-4 production. 13, 25, 31, 32 The mechanism behind this response may not necessarily be directly related to the generation of long-term immunity. It has been shown that recall antigen-specific IL-4 production by splenocytes in the presence of IL-3 can come from IL-3-activated mast cells. 32 This indirect IL-4 pathway can potentially inhibit type 1 T-cell differentiation and may be insufficient to trigger the development of Th2 memory T cells. We have previously observed a basophilic response within IL-3 producing tumors. 12 In the current experiments we did not determine if the IL-4 producing cells were T cells or basophils but, perhaps more importantly, local RT delivered to IL-3 gene-transduced tumors enhanced IFN-g producing Th1 and CTL responses in the spleen and seemed to redirect such responses away from an IL-4 pathway and towards a more potent Th1-type of immunity. Combined with results from our previous studies, 11, 23, 24 there seems little doubt that the tumor regression generated by RT plus IL-3 gene therapy is due to a tumor-specific immune response. Target An important component of the tumor regression process following RT or IL-3 treatment, alone and in combination, may be infiltration of peripheral macrophages as evident by the increase in Mac-1 positive cells. TAMs are the major host cellular components within the tumor microenvironment (see review in Murdoch et al. 33 ), however, their roles in tumor growth remain controversial as they have variably been reported to be both growth promoting 23, 34 and tumoricidal. 23, 35 This may relate to the activation state of the TAMS. Infiltrating TAMs are also likely to be more cytotoxic than those that have been resident for some time. 36 The site within the tumor may also be relevant. A recent study by Ohno et al., 37 showed that high numbers of TAMs in close contact with human endometrial cancers were associated with a high relapsefree survival rate, while the opposite was true if they were found in hypoxia or necrotic areas. It is possible that combining RT and IL-3 therapy alters the tumor microenvironment and redistributes or re-educates the TAMs to become tumoricidial. It may also be critical to know whether these infiltrating Mac1 þ cells can develop into DC cells as reported in other models, 14, 29, 30 which would assist in tumor antigen presentation.
While the effects of IL-3 and RT on host cells are obvious, a less obvious effect of both IL-3 and RT is on tumor cell phenotype. Part of the 'danger' response to irradiation is modification of cellular phenotype that may make cells more effective targets. In the same way, cytokines, such as interferon and IL-3, produced by T cells orchestrate dynamic changes in target cells that make them more sensitive to lymphocyte-mediated killing. Modification of these expression patterns on tumor cells by exogenous gene therapy or RT could therefore be important in enhancing the therapeutic benefit of IT.
We have previously shown that IL-3 gene expression increases the expression of MHC class I, CD44, ICAM-1, and TNFR expression by fibrosarcoma cells. 12 In one case, one fibrosarcoma cell line that was refractory to TNF-a treatment became sensitive after IL-3 gene transduction. 23 In addition to confirming some of these findings in this study using TRAMP-C1 cells, we further found that IL-3-induced Fas antigen expression, as did RT. The effect of RT is similar to recent findings by Chakraborty et al. [5] [6] [7] They have proposed that radiationinduced tumor phenotype changes could enhance tumor cell susceptibility to antigen-specific CTL-mediated killing. The mechanism that mediates this type of phenotypic switch by IL-3 is still unclear. In practical terms, it may in part counteract the radiation-induced suppression in function of DCs in the generation of MHC class I-mediated anti-tumor immunity that we recently reported. 8 We are currently studying this possibility. The combined effects of IL-3 plus radiation may therefore both modulate antigen presentation and alter the tumor phenotype to result in enhancement of immune reactions.
In conclusion, we have demonstrated that the combination of RT and IL-3-based IT can cure mice of TRAMP-C1 tumors. Most notably, IFN-g-directed CTL immune pathway following radiation therapy was enhanced in the presence of IL-3. This is a feasible approach to enhance the efficacy of prostate cancer therapy with minimum side effects. RT and IT is potentially a powerful combination that can increase the chances of achieving local, regional, and systemic control of cancer.
